Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab proof-of-concept study in moderate to severe hidradenitis suppurativa
NL-OMON37989Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- May 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ustekinumab in hidradenitis suppurativa (HS), sponsored by University Medical Center Groningen. Primary endpoints: Clinical response by Sartorius/HS-LASI, Clinical response by Physician Global Assessment and 2 more. Started May 2012; status: active, not recruiting.
02
Drugs
ustekinumab
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON37989.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37989.